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Resumo
Tomografia por Emissa˜o de Positro˜es (PET, do Ingleˆs Positron Emission
Tomography) e´ uma te´cnica de medicina nuclear que se baseia no uso de ra-
diofa´rmacos, permitindo o estudo de mecanismos metabo´licos. Os radionucl´ıdeos
emitem positro˜es no decorrer do tempo, os quais definem uma determinada tra-
jecto´ria ate´ se aniquilarem com os electro˜es presentes no meio, originando dois
foto˜es γ com 511 keV de energia que sera˜o detectados pelo sistema de PET.
Assim, e´ poss´ıvel a obtenc¸a˜o de imagens funcionais para fins de diagno´stico de
diversas patologias.
Todavia, as imagens de PET sa˜o caracterizadas por uma baixa resoluc¸a˜o
espacial em virtude de va´rios factores:
• Alcance dos positro˜es;
• Efeito de Compton que corresponde a` deflexa˜o na trajecto´ria dos foto˜es
γ;
• Atenuac¸a˜o dos foto˜es gama;
• Movimento do paciente, batimento card´ıaco e respirac¸a˜o.
Todos estes factores sa˜o responsa´veis pela ocorreˆncia de PVEs (do Ingleˆs,
Partial Volume Effects) que corresponde a` perda de detalhe e/ou aparente ac-
tividade em pequenos objectos ou regio˜es nas imagens me´dicas. De forma a
minimizar o impacto de PVEs na qualidade das imagens de PET, va´rios pro-
cedimentos designados de PVC (do Ingleˆs, Partial Volume Correction) teˆm sido
desenvolvidos.
Por outro lado, cada te´cnica de imagiologia permite a obtenc¸a˜o de imagens
funcionais e/ou anato´micas para aplicac¸o˜es bem espec´ıficas, contudo todas elas
apresentam limitac¸o˜es. Neste contexto, imagiologia por interme´dio de agentes
bi- ou multimodais surgiu como meio de estudo dos processos biolo´gicos para
fins de investigac¸a˜o, diagno´stico e terapia, uma vez que as potencialidades de
va´rias te´cnicas de imagiologia sa˜o exploradas em um u´nico agente, garantindo
a obtenc¸a˜o de dados mais precisos.
Tendo em conta a baixa resoluc¸a˜o das imagens de PET e as vantagens dos
agentes bimodais, este projecto teve como objectivo avaliar a associac¸a˜o de
nanopart´ıculas detecta´veis por PET e Ressonaˆncia Magne´tica (MRI, do Ingleˆs
Magnetic Resonance Imaging) e procedimentos de PVC para melhorar a qual-
idade das imagens de PET. Mais especificamente, como base deste projecto
foram utilizadas nanopart´ıculas SPIO (Superparamagnetic Iron Oxide) associ-
adas a Flu´or-18 (18F) e o me´todo de PVC denominado SFSRR (Structural and
Functional Information for Resolution Recovery).
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SFSRR foi seleccionado como me´todo de PVC a uilizar neste projecto, uma
vez que este procedimento ja´ demonstrou resultados promissores em estudos
neurolo´gicos de PET quando comparado com outras metodologias standard de
PVC, nomeadamente as te´cnicas de deconvoluc¸a˜o van Cittert e Lucy-Richardson
e o procedimento GTM (Geometrix Transfer Matrix). [32, 67,68].
A realizac¸a˜o deste projecto envolveu quatro fases: (i) realizac¸a˜o de uma
simulac¸a˜o para entendimento do funcionamento do me´todo de SFSRR; (ii)
aquisic¸a˜o de imagens de PET e MRI de um fantoma utilizando um scanner
nanoPET/MRI; (iii) definic¸a˜o de um procolo para processamento dos dados
de fantoma e (iv) aplicac¸a˜o do procedimento SFSRR a dados simulados e de
fantoma.
O Cap´ıtulo 2 inicia-se com a apresentac¸a˜o dos princ´ıpios ba´sicos de PET,
dando especial eˆnfase aos factores que afectam a qualidade das imagens desta
te´cnica (Secc¸a˜o 2.1.3). Por sua vez, sa˜o abordados os conceitos relacionados
com sistemas PET/MRI, agentes de contraste detecta´veis por PET e MRI e
por fim PVC.
No Cap´ıtulo 3 e´ descrito o trabalho desenvolvido no decorrer deste projecto,
mais especificamente a simulac¸a˜o realizada, estrate´gias seguidas para processa-
mento dos dados de fantoma e por fim a aplicac¸a˜o do me´todo SFSRR a dados
simulados e de fantoma.
A simulac¸a˜o realizada consistiu em um quadrado cujos voxe´is possu´ıam a
mesma intensidade 1000 e no exterior 0. Para recriar a baixa resoluc¸a˜o espacial
de PET um filtro Gaussiano foi aplicado, resultando num dos ficheiros de entrada
do me´todo SFSRR denominado PET data. Os outros dois ficheiros de entrada
foram obtidos: (i) ao estimar-se a me´dia dos vo´xeis situados no interior do
quadrado em PET data, originando Segmented PET data e (ii) aplicac¸a˜o de
um filtro Gaussiano a Segmented PET data resultando no u´ltimo ficheiro de
entrada designado Smoothed Segmented PET data. Estes treˆs ficheiros foram
considerados para efectuar a melhoria de qualidade de PET data.
Em termos dos dados reais, os treˆs principais objectivos estudados foram:
• Verificar como o tamanho do objecto influencia a PVC efectuada;
• Analisar a eficieˆncia do procedimento de SFSRR quando va´rias concen-
trac¸o˜es de nanopart´ıculas e 18F sa˜o utilizadas;
• Examinar como a filtragem afecta os resultados obtidos com o me´todo
SFSRR.
Assim, um Cucumis sativus (pepino) foi utilizado como fantoma no qual no
seu interior continha doze tubos com treˆs poss´ıveis diaˆmetros, com o intuito de
explorar a relac¸a˜o entre a dimensa˜o do objecto e PVC:
• Tubo pequeno - 0.5 mm de diaˆmetro;
• Tubo me´dio - 1 mm de diaˆmetro;
• Tubo grande - 1.5 mm de diaˆmetro.
Todos os tubos possu´ıam soluc¸o˜es de nanopart´ıculas associadas a Fluo´r-18,
com excepc¸a˜o de dois que continham a´gua, soluc¸a˜o a considerar como refereˆncia.
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Tal visou estudar como e´ que a concentrac¸a˜o de radioiso´topo e nanopart´ıculas
influencia os resultados de PVC.
O u´ltimo aspecto analisado foi como a filtragem esta´ relacionada com a mel-
horia da qualidade das imagens de PET. Para tal, valores distintos de filtragem
foram utilizados num dos ficheiros de entrada do procedimento de SFSRR, mais
especificamente Smoothed Segmented PET.
Os dados reais foram adquiridos ao realizar-se um exame simultaˆneo de PET-
MRI durante 63 minutos em um scanner Mediso nanoPET/MRI. Imagens pon-
deradas em T2 foram obtidas de forma a explorar a capacidade de contraste
por T2 das nanopart´ıculas SPIO, possibilitando determinar a exacta localizac¸a˜o
espacial dos doze tubos. Por outro lado, as imagens de PET permitiram inferir
a actividade de 18F existente em cada um dos tubos.
O me´todo de SFSRR foi desenvolvido de forma a ser aplicado em imagens
neurolo´gicas de PET, sendo que o procedimento inclui uma estrate´gia para
processamento dos dados de PET e MRI antes de efectuar-se a melhoria das
imagens de PET. Todavia, uma vez que neste projecto foram utilizados dados
de fantoma, uma das etapas do trabalho desenvolvido consistiu na definic¸a˜o de
um protocolo de processamento dos dados.
O protocolo de processamento definido incluiu treˆs softwares: (i) VivoQuant;
(ii) Fiji e (iii) MATLAB.
VivoQuant automaticamente altera as dimenso˜es e tamanho dos vo´xeis dos
dados de PET, de forma a coincidir com as caracter´ısticas da imagem de re-
fereˆncia, neste caso MRI. Igualmente, e´ poss´ıvel reorientar os dados e realizar
transformac¸o˜es espaciais com os dois tipos de dados presentes na mesma janela,
minimizando a ocorreˆncia de erros no decorrer desta etapa.
Por outro lado, Fiji foi utilizado para desenhar a´reas de interesse uma vez
que este software possui uma grande variedade de formas e ferramentas para este
efeito. Outra vantagem e´ a existeˆncia do plugin denominado MIJ que permite
a leitura e troca de dados entre Fiji e MATLAB.
Seguidamente, MATLAB foi seleccionado para: (i) aplicar uma ma´scara aos
dados de PET com o intuito de seleccionar-se somente as contagens de PET
situadas no interior dos tubos; (ii) estimac¸a˜o da me´dia em cada tubo; (iii)
filtragem dos dados e (iv) exportar dados no formato Analyze e tipo double.
Assim, os treˆs ficheiros de entrada do me´todo SFSRR foram criados - PET,
Segmented PET and Smoothed Segmented PET - e foi poss´ıvel efectuar PVC
do ficheiro PET.
Os resultados obtidos e respectiva discussa˜o sa˜o mencionados no Cap´ıtulo 4.
A simulac¸a˜o realizada demonstrou que o procedimento de SFSRR levou a
uma melhoria nos valores ma´ximo e me´dia de PET, em aproximadamente 6.8% e
10.3%. Igualmente, os dados simulados foram criados de tal forma que todas as
fatias tivessem a mesma distribuic¸a˜o de intensidades, contudo a imagem obtida
apo´s a aplicac¸a˜o do me´todo de SFSRR na˜o apresenta esta uniformidade o qual
na˜o era esperado. O esclarecimento desta questa˜o sera´ alvo de estudo futuro.
Seguidamente, o trabalho desenvolvido focou-se na ana´lise de dados de fan-
toma. A existeˆncia de PVEs e´ mais significante para objectos de pequenas
dimenso˜es e na presenc¸a de maiores valores de filtragem. Os resultados obtidos
com o fantoma revelaram maiores diferenc¸as nas contagens de PET em tubos de
menores dimenso˜es contendo maiores concentrac¸o˜es de nanopart´ıculas e 18F, as-
sim como quando maiores valores de filtragem foram considerados. Ale´m disso,
nos outros dois tipos de tubos - me´dio e grande - as maiores melhorias nas
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contagens foram observadas para menores concentrac¸o˜es de SPIOs e 18F, bem
como para valores superiores de filtragem.
Por fim, concluso˜es e perspectivas futuras sa˜o apresentadas no Cap´ıtulo 5.
Os resultados obtidos demonstraram que o procedimento de SFSRR e´ efi-
ciente para minimizar a influeˆncia de PVEs nas imagens de PET. Todavia, e´
importante realc¸ar que o procedimento SFSRR foi desenvolvido de forma a ser
utilizado em estudos neurolo´gicos de PET, pelo que os paraˆmetros existentes
esta˜o optimizados para esta aplicac¸a˜o. Assim, futuramente va´rios paraˆmetros
tera˜o de ser alterados com vista a que o me´todo seja adaptado aos dados de fan-
toma utilizados no decorrer deste projecto. Igualmente, mais estudos com dados
simulados e reais tera˜o de ser efectuados para melhor entender-se os resultados
iniciais.
Palavras-chave: Nanopart´ıculas bimodais; Tomografia por Emissa˜o de
Positro˜es; PVC; SFSRR.
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Abstract
Positron emission tomography (PET) images are characterized by a low spa-
tial resolution mainly due to: (i) radioisotopes’ positron ranges; (ii) scatter; (iii)
attenuation; (iv) parallax error or radial elongation and (v) motion. Due to these
aspects, partial volume effects (PVEs) can occur which are characterized by loss
of detail and/or apparent activity in small objects or regions at spatial and/or
time levels. Partial Volume Correction (PVC) methodologies aim to minimize
the impact of PVEs in PET images [4, 8, 73].
Also, dual- or multi-modality imaging arise from the combination of two
or more imaging techniques based on the use of multi-modal probes, ensuring
a better visualization of biological processes and acquisition of more accurate
data.
In this context, this project aimed to evaluate the potential of combining
PET/MRI nanoprobes and PVC procedures for improving the quality of PET
images. More specifically, superparamagnetic iron oxide (SPIO) nanoparticles
combined to 18F radioisotope and the PVC method named SFSRR (Structural
and Functional Information for Resolution Recovery) were used as basis of the
work developed in this project [32,67,68].
The simulation study performed showed that the SFSRR procedure led to
an average improvement of 6.8% in maximum and 10.3% in mean values. Ad-
ditionally, the tracer’s activity distribution was equivalent in all slices of each
input data, however this uniformity was not observed in recovered data. Thus,
this aspect will be clarified in future work.
PVEs are more significant for smaller objects and greater smoothing values.
Phantom data results demonstrated larger uptake differences in small tubes
containing a higher concentration of SPIOS-18F and for greater smoothing val-
ues. In contrast, higher quantification deviations in medium and big tubes
were detected for lower isotopes’ concentrations and greater smoothing values,
especially in medium tubes.
The results obtained showed that the SFSRR procedure is efficient for mini-
mizing the influence of PVEs in PET images. Nevertheless, further experiments
are required for better understanding the initial results.
Keywords: bimodal nanoparticle imaging agents; PET; Partial Volume
Correction; SFSRR.
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Chapter 1
Introduction
PET images are characterized by a low spatial resolution and lack of mor-
phological information as a result of several factors: (i) positron range of the
radioisotopes; (ii) scatter; (iii) attenuation; (iv) parallax error or radial elonga-
tion and (v) motion [4, 8, 73].
Partial Volume Correction (PVC) methodologies have been developed in
order to minimize the aspects mentioned previously and improve PET images
quality.
On the other hand, molecular imaging is a scientific area dedicated to the
non-invasive study of biological processes. It assumes an important role in un-
derstanding the molecular abnormalities that are the basis of diseases and corre-
sponding molecular alterations, guaranteeing an earlier disease characterisation
and detection, as well as the evaluation of possible and important treatments.
Various imaging modalities - PET, MRI, SPECT (Single Photon Emission
Computed Tomography), optical and ultrasound - can be used to assess the
molecular targets. Although each imaging modality provides functional and/or
anatomical information suitable for certain applications, all present intrinsic
limitations. In this context, dual- or multi-modality molecular imaging arise
from the combination of two or more imaging techniques based on the use of
multi-modal probes, ensuring a better visualization of biological processes and
acquiring more accurate data.
Bimodal nanoprobes have been developed, including nanoparticles that com-
bine: (i) the high sensitivity of fluorescence imaging with the good contrast
achieved with MRI; (ii) the high resolution of MRI with the high sensitivity
and functional information characteristic of PET, obtaining data that contem-
plates both anatomy and functionality; (iii) high soft tissue contrast of MRI and
high sensitivity of SPECT, however the latter one has a lower spatial resolution
than PET [30].
Taking into account the low spatial resolution of PET images and the ad-
vantages of dual modality agents, this project aimed to evaluate the potential
of combining PET/MRI nanoprobes and PVC procedures for improving the
quality of PET images. More specifically, superparamagnetic iron oxide (SPIO)
nanoparticles combined to 18F radioisotope and the SFSRR PVC method were
used as basis of the work developed.
SFSRR was selected as PVC method to apply in this project because it al-
ready showed promising results in PET brain studies comparing to other com-
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mon PVC routines, more specifically van Cittert and Lucy-Richardson decon-
volution techniques and also Geometric Transfer Matrix (GTM) approach.
The work developed consisted in: (i) performing a simulation study; (ii)
acquiring PET and MRI datasets using a PET/MRI preclinical scanner; (iii)
defining a processing protocol for phantom data and (iv) applying the SFSRR
procedure to simulated and phantom data.
This thesis starts in Chapter 2 with a description of the basic concepts of
PET, with special emphasis on the aspects that affect the quality of PET images
(Section 2.1.3). Then, PET/MRI Systems, PET/MRI contrast agents and PVC
aspects are described in detail.
In Chapter 3 is discussed the simulation study done and also the strategies
followed for defining a processing approach suitable to phantom data. Finally,
the PVC performed to simulated and phantom datasets is mentioned.
The results obtained and respective discussion are referred in Chapter 4.
Finally, conclusions and future perspectives are presented in Chapter 5.
2
Chapter 2
Theoretical Background
This chapter provides a background of the main topics that are covered in
this thesis. Section 2.1 presents the physical concepts of PET, giving special
emphasis to the factors that affect the quality of PET images. Then, PET/MRI
systems are described in Section 2.2 and related with the use of PET/MRI
nanoparticle agents in Section 2.3. The influence of PVES in PET and existing
PVC approaches are discussed in Section 2.4. Finally, Section 2.5 mentions
certain studies done in PET/MRI nanoprobes and PVC areas.
2.1 Positron Emission Tomography
2.1.1 Radionuclides and Positron Emission Decay
PET is a nuclear imaging technique that allows to assess functional processes
by using a radiotracer which consists in a radioactive isotope associated to a
molecule with specificity to a certain metabolic process.
PET radioisotopes, also known as radionuclides, emit positrons – positron
decay – where a proton ρ+ from the unstable radionuclide is converted into a
neutron n by emitting a positron β+ and a neutrino ν [4]:
ρ+ → n+ β+ + ν (2.1)
Assuming that N is the number of radioisotopes in the sample and α is the
isotope decay constant, the decay probability per time unit or radioisotope’s
activity can be defined as [73]:
dN(t)
dt
= −N(t)α (2.2)
where dN(t)dt is the radioisotope’s activity that has Becquerel (Bq) as units
and the negative sign represents the decrease in the number of atoms as time t
increases.
The general solution of the differential Equation 2.2 for a time period dt =
t− t0 is [73]:
N(t) = N(t0)e
−α(t−t0) = N(t0)e−
t−t0
τ (2.3)
where N(t0) is the initial number of atoms when t = 0 .
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The radioisotope decay obeys to an exponential function. It has τ = 1α
as time constant and T 1
2
= ln 2τ = 0.69τ is the radioisotope half-life, which
corresponds to the time required for 50% of the nuclei to disintegrate (Figure
2.1).
Figure 2.1: Radioisotope decay. N(0) is the initial number of radionuclides, τ
is the exponential decay time constant and T 1
2
is the half-life of the radioactive
isotope.
The most common radionuclides used in PET are: Carbon-11, Nitrogen-13,
Oxygen-15, Fluorine-18 and Gadolinium-68 (Table 2.1).
Isotopes T 1
2
(min)
11C 20.40
13N 9.96
15O 2.03
18F 109.80
68Ga 68.30
Table 2.1: PET most common radioisotopes and corresponding T 1
2
values [4].
The positron originated from the positron decay will suffer a decrease of its
energy and change in its original path by interacting with other nuclei.
When the kinetic energy of the positron is sufficiently low, a positron-electron
annihilation will occur, i.e., the collision of a positron β+ and an electron (e−)
will originate two gamma photons emitted in 180 degrees opposed directions
and with an energy of 511 keV (Figure 2.2).
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Figure 2.2: Schematic representation of a positron-electron annihilation.
Equation 2.4 describes the electron-positron annihilation process [8]:
β+ + e− → γ + γ (2.4)
The distance travelled by the positron until the annihilation occurs is called
the positron range and it depends on the nature of the radioisotope used.
2.1.2 Detection of gamma photons
Inside the PET scanner, an array of detectors is displayed cylindrically
around the object in order to detect the gamma photons from electron-positron
annihilation events.
As mentioned previously, for a given annihilation event two gamma photons
of 511 keV are emitted at almost 180 degrees to each other. In PET systems, two
detectors are required to detect the γ-photons of the same pair. So, whenever
two gamma photons are detected by distinct detectors within a timing window
of around 1-10 nanoseconds, the detection is classified as a coincidence event.
Thus, the radioactive source can be localized by defining a straight line between
both detectors, designated as Line-Of-Response (LOR).
By estimating the intersection of all LORs, the location of the radiation
source can be estimated more accurately.
There are three categories of coincidence events (Figure 2.3):
• True events - when both γ-photons originated from the same annihilation
event are detected without suffering any interaction before detection;
• Scatter events - at least one of the detected photons underwent one or
more Compton scatter events. If scattered photons are considered by the
detector system, incorrect LORs will be defined;
• Random events - this occurs when two γ-photons detected are from dis-
tinct annihilation events and consequently a wrong LOR will be assigned.
This happens when two radionuclides decay by chance within the same
timing window.
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Figure 2.3: Top: True event. Middle: Scatter coincidence. Bottom: Random
event.
If more than two γ-photons are detected by the PET system in the same
timing window, the event will be rejected as it is not possible to determine which
LOR is the correct one.
Assume that a certain LOR represents a s-axis and a point source is located
in s = a which emits N(a) photons along this axis, as well as that two detectors
are positioned, respectively, in s = d1 and s = d2.
According to a certain LOR, the gamma photons will pass through tissues
with different characteristics and thicknesses which will translate into distinct
linear attenuation coefficients µ. The value of µ indicates the fraction of photons
that interact per unit distance ds of a certain material. It is characterized by
the atomic number Z, density of the material and photons’ energy.
The number of photons that interact within a small distance unit ds will
depend on µ of the tissue and on the initial number of photons originated
N(a) [73]:
dN
ds
= −N(a)µ (2.5)
The solution of Equation 2.5 is [73]:
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N(s) = N(a)e−sµ (2.6)
The different attenuation coefficients that exist for each small spatial portion
ds must be considered when estimating the number of photons that reach each
detector, so [73]:
N(d1) = N(a)e
− ∫ d1
a
µ(s)ds (2.7)
N(d2) = N(a)e
− ∫ d2
a
µ(s)ds (2.8)
As photons from the same annihilation event define independent trajectories,
the detection probabilities can be multiplied [73]:
N(d1, d2) = N(a)e
− ∫ d1
a
µ(s)dse−
∫ d2
a
µ(s)ds = N(a)e−
∫ d2
d1
µ(s)ds (2.9)
Figure 2.4 represents the detection of γ-photons in a PET camera.
Inside the detectors, scintillation crystals absorb the γ-photons via photo-
electric absorption and photoelectrons are created.
During the photoelectrons displacement through the crystal, they will col-
lide with other electrons present in the medium, originating light (scintillation)
photons which are conducted to a photodetector, generally a photomultiplier
tube (PMT). A PMT consists of a photocathode and a set of dynodes. Firstly,
the photons hit the photocathode, releasing some electrons which then are ac-
celerated towards the closest dynode. As the voltage becomes systematically
higher with the distance, the electrons acquire higher speeds activating more
additional electrons in every stage. Finally, the obtained signal is amplified by
an amplifier located next to the PMT and an event is recorded.
Figure 2.4: Detection of gamma-photons in PET.
7
2.1.3 Image Quality
PET images are affected by several factors which will be described in more
detail below.
2.1.3.1 Positron Range
The main interest in PET is to infer the location of the decaying nucleus and
not where the photon-producing event took place. However, the positron travels
a finite distance before the annihilation occurs - positron range - which will lead
to uncertainties in figuring out where the radionuclide nucleus is located. This
aspect will affect the spatial resolution obtained in PET.
The positron range value depends on the nature of the radioisotope that
originated the positron. For example, more energetic positron-emitting ra-
dionuclides have a higher positron range (Table 2.2), which will compromise
more significantly the quality of PET images.
Isotopes Emax positrons (MeV) Mean range in water (mm)
11C 0.959 1.1
13N 1.197 1.5
15O 1.738 2.5
18F 0.633 0.6
68Ga 1.898 2.9
Table 2.2: Properties of the most common PET radioisotopes [4, 20,31].
2.1.3.2 Scatter
The γ-photons can suffer one or more Compton scatter events during their
displacement. The resulting deflected photons have a lower energy and a change
in their original trajectory.
The scattered photons have a lower energy than 511 keV, so the PET sys-
tem can use this feature to suppress them as much as possible. However, some
deflected photons are considered as coincidence events and consequently inco-
herences will occur.
Firstly, incorrect LORs will be defined which results in an overestimation of
the tracer’s concentration in certain regions, because counts that were not from
these spatial locations will be contemplated.
As the accuracy of the quantitative measurements is affected, the contrast
will also be compromised. More specifically, the contrast is estimated based on
intensity differences detected between adjacent regions of an image and this is
inferred based on the measured PET counts. If initially the detection is not
precise, then the contrast will also be affected.
2.1.3.3 Attenuation
Attenuation in PET occurs mainly because of Compton scatter events and
the chemical composition of tissues.
In Compton scatter events, the γ-photons experience a decrease in their
energy.
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Additionally, the energy of the photons can be attenuated based on differ-
ences in tissues characteristics and thicknesses (distinct attenuation coefficients).
In both cases, the photons from the same annihilation will have different
energies, and so this pair will not be recognized as a coincidence event.
If several coincidence events are lost due to attenuation, then the number of
PET counts from a certain region are underestimated.
This effect can be minimized by applying attenuation correction procedures
which are performed based on transmission scans.
In a transmission scan, a source that emits radiation in a known range of
energies (generally 68Ge rod source or 137Cs point source) is rotated around
the patient. When the radiation passes through the patient body, its energy
will be attenuated and is detected by the PET system, originating an image
designated as transmission scan. The attenuation factors are estimated for each
γ-photons pair, i.e., each LOR. They can be calculated in accordance with
Equation 2.10 [4, 73]:
N0
N
= e−
∫ d2
d1
µ(s)ds (2.10)
where N0 is the number of photons detected in the emission scan between
two detectors located in s = d1 and s = d2, N is the number of photons
counted between the same detectors in the transmission scan and µ is the linear
attenuation coefficient.
The transmission data can be considered during the reconstruction of the
emission data, improving its quality.
Another attenuation methodology is available in PET/CT scanners. PET
data is acquired and then a CT scan is performed and used to create a 511 keV
attenuation map. This approach can introduce artifacts if PET and CT data
are not correctly registered.
Finally, nowadays MRI guided attenuation correction procedures are also
available, however they are not as efficient as CT based procedures. This occurs
because MRI signal is not electron density dependent which complicates the
determination and location of the major attenuating structures. As a conse-
quence, it is more challenging converting MRI data into attenuation maps than
using CT images.
2.1.3.4 Parallax error or Radial elongation
The gamma photons that strike detectors located in the gantry edges will
interact with the scintillation crystal according to a certain angular divergence.
Therefore, there is less material to stop the gamma radiation, and so the photon
will suffer a spillover of its trajectory and will interact with the adjacent crys-
tal. This aspect compromises the quality of PET images as the radioactivity
detect near gantry edges has worst resolution (wider Full-Width-Half-Maximum
- FWHM) than in the center. The spatial resolution is expressed in terms of
FWHM which corresponds to the minimum distance that two point sources
positioned very close are seen as separate in an imaging system.
2.1.3.5 Motion
PET scans last longer than other imaging modalities, therefore the effect of
motion in PET image quality is more significant.
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Motion artifacts can occur due to changes in patient’s position during the
scan, respiration, cardiac motion, peristalsis or bladder filling. In order to over-
come these aspects, motion correction procedures need be used which efficiency
decreases significantly in presence of intense tissue-movement.
2.2 PET/MRI Systems
PET and SPECT have a high sensitivity to assess metabolic pathways in
the picomolar range by using radiotracers. However, these nuclear imaging
techniques have a low spatial resolution, compromising the accurate spatial
detection of the decaying nuclei locations. In contrast, CT and MRI have a
good anatomical contrast but a low sensitivity.
As a consequence, in order to ensure a proper diagnosis and/or treatment
planing, generally SPECT or PET images are combined with CT or MRI data
through registration procedures.
In this context, since the late 1990’s medical devices that integrate different
imaging modalities in the same system have been developed which are desig-
nated as Hybrid imaging devices [8]. Thus, these systems combine the advan-
tages of each imaging technique. At the present, there are three types of hybrid
devices: SPECT/CT; PET/CT and PET/MRI.
The first hybrid imaging equipment created was SPECT/CT in 1998 followed
by PET/CT in 2000. More recently, PET/MRI systems have been developed [8].
Over the last years, PET/MRI systems have achieved a great relevance in
comparison to PET/CT scanners due to several aspects.
On the one hand, MRI images have a higher contrast and greater spatial
resolution than CT, as well as this modality provides a wider range of informa-
tion - structural, functional, diffusion, spectroscopy, angiography and perfusion.
Also, MRI does not expose the patient to additional radiation in contrast to
what occurs in PET/CT scanners. However, attenuation correction procedures
are more efficient when using CT data as basis than MRI images.
On the other hand, PET allows the study of metabolic processes with high
accuracy and sensitivity, nevertheless its spatial resolution is low due to positron
range, scatter, attenuation and motion (2.1.3).
Table 2.3 summarizes the advantages and limitations of MRI and PET.
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Modality Spatial resolution Advantages Limitations
MRI
Tens of micrometers
(preclinical systems)
High resolution Low sensitivity
(10−3− 10−5mol/l)
1 mm (clinical sys-
tems)
Good contrast High cost
Physiological and
anatomical details
Artifacts due to
metallic devices in
patients
PET
1 mm (preclinical
scanners)
Study of metabolic
processes
Radiation
4-6 mm (whole-body
systems)
High sensitivity
(10−11−10−12mol/l)
High cost
Lack of anatomical
information
Table 2.3: Comparison between MRI and PET systems. [5, 8, 12,26,56,88]
Based on the features mentioned in Table 2.3 is possible to conclude that
MRI and PET are really distinctive in terms of resolution, sensitivity and type
of information provided. As a consequence, these imaging techniques are com-
monly combined, either in separate scanners or in PET-MRI systems, in order
to obtain more accurate information.
Figure 2.5: Two possible geometries for PET-MRI systems. Left: NSiPM sys-
tem where PET and MRI are axially displaced and the scans are acquired se-
quentially. Right: SiPm consists in placing the PET scanner within the MRI
magnet such that PET and MRI scans are performed simultaneously.
There are two types of PET-MRI systems:
• Non-Simultaneous PET-MRI (NSiPM) – in this system the patient lies
on the bed that moves automatically and alternatively between PET and
MRI scanners. Images are sequentially acquired, i.e., the data from both
imaging modalities is acquired in distinct time periods. Thus, a registra-
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tion procedure must be carried out so that PET and MRI data can be
analysed together;
• Simultaneous PET-MRI (SiPM) – allows acquiring simultaneously PET
and MRI images. Therefore, it will be possible to overcome the coregis-
tration errors induced by organ and/or patient motion as real-time MR
and PET images are available. This approach assumes quite relevance in
biological studies where the radiotracers response is highly dynamic and
time dependent.
Regarding the disadvantages of NSiPM, in this technology PET and MRI im-
ages are acquired separately and then registered. The registration is performed
based on image data contents (e.g., landmarks) or external markers existing
in the images subjected to registration. Registration gives good results in the
brain, but becomes more difficult for other parts of the body, which result from
the change in patient’s position in the scanner bed, respiration, cardiac motion,
peristalsis or bladder filling. In order to overcome these aspects, deformable
(non-rigid) image registration techniques can be used, but their efficiency de-
creases significantly in the presence of severe tissue-movement.
Another limitation of NSiPM system is that during the acquisition of images
from one modality, the other scanner must remain idle. As a consequence, a
higher scanning time is required which is not ideal for assessing the radiotracer’s
concentration when it is highly variable in terms of time and biodistribution.
On the other hand, SiPM system faces several problems which are:
• Electromagnetic interference due to MRI magnetic radiofrequency pulses
and gradient coils, or because of PET electronic system that has radiofre-
quency emitting components which can interfere with the MRI system;
• Effect of MRI main magnetic field on PET detectors, more specifically,
classic photomultiplier tubes used for detecting gamma photons cannot
operate properly in the presence of a magnetic field;
• Induction of eddy currents – the MRI scanner has a permanent magnetic
field, however during the pulse sequences there is a rapid variation of mag-
netic field gradients. As a result, the conductive structures are subjected
to changes in the magnetic field and electric currents can be induced in
PET conductive materials;
• The increase of vibrations and temperature due to MRI sequences will
affect the ideal conditions for PET imaging;
• Susceptibility artefacts occur when the PET system is located inside the
MRI magnet.
Taking into account SiPM limitations, the design of PET electronic compo-
nents has to be adapted to MRI magnetic features in order to merge these two
imaging techniques in the same unit.
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2.3 Contrast Agents
2.3.1 Nanoparticles
Iron oxide nanoparticles generally consist of three parts (Figure 2.6):
• core - metallic nature which is responsible for enhancing the MRI signal;
• shell - confers biocompatibility to nanoparticles in order to avoid their
degradation and initiate an immune response;
• bioactive materials - elements associated to nanoparticles’ surface for
targeting purposes.
Nanoparticulate materials have achieved a great importance in molecular
imaging for several reasons:
• Internal volume – can be used for transporting and delivering imaging and
therapeutic agents;
• Large surface area – nanoparticles can be associated to a high number and
variety of active elements, improving physical and/or chemical interactions
and reactivity;
• Non-invasive approach for monitoring biological processes, in terms of drug
delivery, response to therapeutic agents and imaging detection;
• High sensitivity achieved when combining them with antibodies and other
targeting agents;
• Multimodal imaging – conjugation with different probes for being de-
tectable by distinct imaging modalities.
Based on these features, nanoparticles assume a big relevance in imaging as
they can transport and deliver a big quantity of contrast agents until the target
area – high sensitivity – as well as they can be associated to different probes in
order to be detectable by distinct imaging modalities.
Also, nanoparticles face several challenges which are:
• High tissue-selectivity without significant intervention of the RES (retic-
uloendothelial system);
• Non-toxicity;
• Full clearance from the system;
• Non-immunogenicity.
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Figure 2.6: The structure of a nanoparticle.
2.3.2 MRI contrast agents
MRI reveals the anatomical details with good spatial resolution and contrast,
however sometimes it is a challenge to distinguish certain tissues, for instance,
normal and diseased tissues, due to small differences in their specific relaxation
times.
This aspect can be minimized by using MRI contrast agents which can be
categorized in: T1 contrast agents and T2 contrast agents.
2.3.2.1 T1 contrast agents
T1 contrast agents are based on paramagnetic atoms and are responsible
for shortening the T1 relaxation time of protons located nearby these agents
by exciting protons from high-energy to low-energy states. This will lead to
a hypersignal in their locations which results in brighter areas in T1-weighted
images.
Magnetization of paramagnetic complexes only occurs in presence of an ex-
ternal magnetic field and it is directly related with the number of paramagnetic
ions present in the target tissue. The most common paramagnetic agents used
are: (i) Gadolinium (Gd3+) and (ii) Manganese (Mn2+).
2.3.2.2 T2 contrast agents
T2 contrast agents are based on superparamagnetic compounds that consist
of iron oxide nanocyrstals, usually magnetite Fe3O4 or maghemite γ-Fe2O3,
and they can be classified in:
• Superparamagnetic iron oxide (SPIO) - approximately 60-150 nm;
• Ultrasmall superparamagnetic iron oxide (USPIO) - approximately 10-40
nm [11,78].
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Superparamagnetic compounds can be magnetized by an external field as
paramagnets, however they have a larger magnetic susceptibility. More specif-
ically, in paramagnetic materials each atom is influenced independently by the
magnetic field while in superparamagnetic compounds the entire magnetic mo-
ments of the atoms tend to align along the external magnetic field, which leads
to a higher strengthening of the magnetic field. When the external magnetic
field disappears, their magnetization decreases to zero as there are fluctuations
in the magnetization direction of individual atoms.
Based on the previous property, superparamagnets show a strong magneti-
zation, creating local field inhomogeneities. This will lead to the decrease of
T2 and T2* relaxation times of the tissues where superparamagnets are located
through the loss of coherence of the local protons, resulting in a hypo-intensity
(dark contrast) of these areas in T2-weighted images.
2.3.3 PET/MRI nanoparticle agents
MRI is one imaging technique that has good spatial resolution and tissue
contrast, however it has low sensitivity. When using nanoparticle agents in MRI,
there is an improvement in the MR signal, resulting in images with a better
spatial resolution and contrast. This assumes a great relevance in diagnostic
and treatment purposes.
On the other hand, radiolabeled nanoprobes in PET allow the study of
biological mechanisms with high sensitivity and accuracy. However, a major
limitation of PET is that it cannot provide anatomical information, preventing
the precise spatial detection of the imaging agents.
Since each imaging modality cannot provide all types of required informa-
tion, the development of new hybrid devices that combine different imaging
techniques has been focus of research.
All these aspects led to the development of multimodal nanoparticle agents
which consist in nanocarriers associated to probes, enabling their detection by
more than one imaging technique. Therefore, it is possible to combine the
advantages of distinct modalities, and additionally improve data acquisition
and guarantee a better non-invasive diagnosis and treatment.
Generally, PET/MRI nanoparticle agents have three components:
• core;
• targeting molecule - that has high affinity towards the biological target;
• radiotracer group - can be directly linked to the nanoparticle surface or
through a spacer group, which can be a hydrocarbon chain, peptide se-
quence or a poly-ethyleneglycol (PEG) linker.
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Figure 2.7: Schematic structure of a PET/MRI nanoprobe.
2.4 Partial Volume Correction (PVC)
2.4.1 Partial Volume Effects
Positron emission faces several problems as explained previously in Section
2.1.3:
• Positron range;
• Scatter;
• Attenuation;
• Parallax error or radial elongation;
• Motion.
Due to these aspects, partial volume effects (PVEs) can occur which are
characterized by loss of detail and/or apparent activity in small objects or re-
gions at spatial and/or time levels, compromising the anatomical or functional
information obtained.
There are three different categories of PVEs:
• Spill-over;
• Sampling effect;
• Temporal aspects.
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Figure 2.8: Point source of uniform activity (100 arbitrary units) in a nonra-
dioactive background corresponds to a measured image in which part of the
signal emanates and is seen outside the actual source. Maximum activity in
measured image is reduced to 85.
Spill-over generally occurs when the object size is two or three times smaller
than the FWHM of the PET image [72]. Therefore, smaller objects tend to be
more affected by PVEs, resulting in a more significant spill-over of the tracer’s
distribution in the object:
Spill-over⇒ Object size < (2 or 3)× FWHM (2.11)
There are two types of spill-over:
• Spill-out - the radioactivity detected on the region-of-interest (ROI) is
higher than in the adjacent areas, which spreads into the neighbour tissues.
Consequently, there is an underestimation of the tracer’s uptake;
• Spill-in - when the surrounding areas have higher activity than the ROI,
their activity will spill into the ROI. Thus, the uptake will be overesti-
mated.
Figure 2.9: In PET, the measured image results from the combination of spill-
out and spill-in effects.
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Image sampling, also known as tissue-fraction effect, can contribute to PVEs
when within each voxel there are different tissue types which might have distinct
tracer concentrations. In this case, the value given to the voxel with mixed tis-
sues is the mean activity, which does not describe the true tracer’s distribution.
Additional PVEs can arise due to temporal factors:
• Blurring because of the heartbeat, respiration or patient motion;
• In dynamic studies, the change in the radiotracer’s activity and distribu-
tion over time.
All these factors affect PET images both qualitatively and quantitatively.
2.4.2 PVC procedures
In order to minimize the impact of PVEs in PET images, several strategies
have been proposed – Partial Volume Correction (PVC) methodologies - that
aim to restore the true activity distribution of the object.
The tissue-fraction effect just can be improved if anatomical information,
CT or MRI, are included during PVC.
In terms of the PVC methods available, they can be categorized in:
• Reconstruction methods;
• Postreconstruction methods.
Each category includes region-of-interest (ROI) and voxel-based approaches.
ROI methods estimate the tracer’s uptake in each region and then its original
value is modified according to the recovery model applied. These approaches do
not originate PVE-corrected images, but instead change the corrected regional
activity values. Therefore, they are only suitable for quantification purposes
and not for visual analysis [72]. On the other hand, voxel-based methodologies
produce PVE-corrected images which are characterized for being more mathe-
matically complex and rely on the use of structural images.
In addition, some methods are performed just based on the data available,
while others also consider anatomical information.
It is important to highlight that there is not an optimal PVC method for
all possible PVEs. It depends on the intended application of the acquired PET
images [21]. So, different types of PVC techniques are described in this section.
2.4.2.1 Post-reconstruction methods
Post-reconstruction PVC methods are applied directly in the reconstructed
image.
Iterative Deconvolution methods
Iterative deconvolution methods are data-driven and involve performing mul-
tiple comparisons between the measured data values and the values estimated
according to the deconvolution model, in order to estimate the true tracer’s
activity.
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Deconvolution procedures do not need homogeneity assumptions which con-
sider that the estimation of the radiotracer’s uptake in a certain structure or
region is independent from others’ structures activity, which it is not true in all
cases. On the other hand, deconvolution approaches have difficulty in control-
ling noise amplification, compromising the efficiency of the PVC performed.
Noise correction can be achieved during deconvolution by including high res-
olution data and regularisation.
Two common deconvolution techniques are:
• Richardson-Lucy algorithm - it is a Bayesian approach where the noise
present in the data is assumed to obey to a Poisson distribution [75,79];
• van Cittert method - aims to estimate the true tracer’s activity that equals
the measured distribution and the blurred version (obtained by iteratively
deconvolving an image with a known PSF - Point Spread Function) based
on the application of a least-square approach [79].
Inclusion of anatomical information
Another methodology available consists in combining the high frequency
information of structural images, CT or MRI, with PET functional data. This
will result in an improvement of the contrast and anatomical details in PET
images.
For this purpose, PET emission data and anatomical images are registered,
so it is possible to know the accurate location of the different structures and use
this information for correcting the tracer’s distribution.
However, the effectiveness of these methodologies depends on: (i) PET and
structural images’ registration and (i) segmentation of the anatomical image, if
required.
Some methods included in this category are:
• Geometric Transfer Matrix (GTM) [59]
GTM obeys to the following steps:
1. A MRI image is segmented into multiple regions;
2. In each ROI, a regional spread function is estimated and a blurred
version is created which just contemplates the activity in this area.
Each ROI is assumed to have uniform activity, so it is valid to describe
the regional tracer uptake by the mean value;
3. It is verified which ROIs have higher or lower activities;
4. The true activity distribution is computed based on the information
obtained in 2) and 3).
• Boussion et al [9] - involves the use of the wavelet transform for extracting
high frequency information from CT or MRI images. Then, it is estimated
the existence or absence of correlation between structural and PET images
in different regions. If there is correlation in a specific region, then the
high frequency components of the anatomical image are incorporated in
PET image, if not PVC is not performed in this ROI.
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• SFSRR (Structural and functional Information for Resolution Recovery)
- was developed by Shidahara et al [68]. It is a modified approach of
Boussion et al [9] method, however in this case a brain atlas is used to
segment the anatomical prior. This procedure was used in this project
and a full description is given in Section 2.4.5.
2.4.2.2 Reconstruction-based methods
An alternative is to perform PVC during the reconstruction procedure. This
strategy has two main benefits: (i) modelling scanner resolution is easier in
projection data than in the image domain and (ii) the noise present in the
projection domain obeys to a Poisson distribution while in the image space
does not assume a particular behaviour/distribution.
As a result, there is a minimization of PVEs in magnitude and a better
control of noise, however quantitative correction is limited by the prevalence of
some residual PVEs which might be difficult to estimate due to the non-linearity
of reconstruction methods.
Resolution Recovery
Simulations related with the PSF of the imaging system aim to explore
the spatially-variance between PET tracer’s biodistribution and the measured
counts.
The derived/modeled PSF can be considered in the system’s matrix which
then is reconstructed, in order to correct physical factors such as scatter, at-
tenuation and motion, as well as to improve the accuracy of the quantitative
measurements.
The quantitative correction using this approach is limited by the prevalence
of some residual PVEs as they are difficult to estimate due to the non-linearity
of some reconstruction methods.
One example of a resolution recovery method was developed by Comtat et
al [13] in 2008, where the system matrix includes the measured projection data
and a modelled space-invariant Guassian PSF that covers the blurring effects of
the PET scanner. Then, the system matrix was reconstructed by using OSEM
(Ordered Subsets Estimation Method) and the results obtained showed that a
higher tracer’s uptake was detected in small structures when this model was
applied.
Anatomical priors
Structural information can be associated during the image reconstruction
step and their main goal is to suppress noise.
Usually anatomical priors are smoothed so that is possible to minimize the
noise present in the data and emphasize the important details in images.
In terms of the different procedures that combine anatomical priors to func-
tional data, some examples are:
• Sastry and Carson (1997) [62] created a maximum a posteriori (MAP)
algorithm which basis is a MRI segmented image for classifying tissues
20
according to their composition. Then, each region is associated to the
corresponding activity;
• Bowsher et al (2004) [10] – first of all the structural images are subjected
to smoothing for reducing any existing variations between voxels with
similar MRI signals. As a result, the filtering step will emphasize voxels
that differ anatomically and thus more accurate results are obtained when
using anatomical data for SPCET or PET images resolution recovery;
2.4.3 Efficiency of PVC procedures
The efficiency of PVC procedures is influenced by the aspects that will be
discussed below.
2.4.3.1 Image Registration
Certain PVC methods use a priori anatomical data for improving the res-
olution of PET images. In this case, the efficiency of the PVC performed is
partially dependent on the accurate registration between structural and func-
tional images.
Image registration errors will affect the new PET counts estimations, com-
promising the veracity of the results obtained.
2.4.3.2 Image segmentation
Additionally, PVC can be affected by image segmentation if the PVC pro-
cedure requires any segmented data.
Incoherences in the segmentation step occur at region level, while misregis-
tration errors influence the entire image.
2.4.3.3 Tissue inhomogeneity
The structural and functional features of the tissues can influence the PVC
methods.
Depending on the conditions that tissues are subjected, their activity can
vary. Also, tissues’ components may not be uniformly distributed.
Thus, the tracer’s distribution in a region or tissue can be heterogeneous
and consequently the homogeneity hypothesis which several PVC methods are
based on will compromise the results obtained.
One possible solution for this aspect consists in performing inhomogeneity
tests - Krylov subspace iteration - in order to evaluate if it is viable to assume
that a certain tissue has an homogeneous tracer’s distribution in all its extension.
The limitation of this test is that it just gives accurate results when associated
to a noise model [60].
2.4.3.4 Gibbs artifacts
Gibbs artifacts are characterized by the existence of a brilliant or dark lines
in the boundary of tissues or areas with distinct tracer concentrations.
In certain occasions PET reconstructed images show Gibbs artifacts which
can occur due to:
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• Information loss resulting from the limitations of the detector system;
• Insufficient data as the voxels dimensions are too large.
2.4.4 Applications of PVC
PET images are influenced by several degrading factors, inducing PVEs that
will affect the accuracy of the quantitative measurements performed. Thus, PVC
is relevant for providing true functional information about physiological and
biological processes. This information might be applied on tumor metabolism
quantification, cerebral blood flow, myocardial perfusion, glucose metabolism
and neuroreceptor binding, however PVC is not a common routine in clinical
practice [60].
The main applications of PVC have been: brain imaging; cardiology and
tumor imaging.
Neurodegenerative diseases, such as Alzheimer’s disease, are characterized
by atrophic changes, particularly in cortical grey matter. Atrophy causes the
thinning of cortical structures, which in turn become more susceptible to PVEs
and so the use of PVC procedures guarantee a more accurate visual of any
anatomical changes.
PVC has also contributed to clarify and/or support important findings in
brain PET imaging. In Alzheimer’s disease, the decrease in glucose metabolism
detected does not correspond to an artefact due to the existence of a bigger
CSF (Cerebrospinal Fluid) space, but in reality it reflects a metabolic alteration
resulting from this pathology. Additionally, PVC has highlighted that there is
a decrease in dopa-decarboxylase activity in Parkinson’s pathology [60].
In terms of cardiology, spillover of the activity from the blood pool towards
the myocardium wall is a common problem in myocardium studies. In this
case, PVC procedures can be used for guaranteeing more accurate quantitative
and flow measurements in myocardial perfusion imaging. Also, the possibility of
correlating PET data with structural images (CT or MR) during PVC improves
the spatial discrimination of the activity uptake detected in blood’s pool and
myocardium, as well as it helps to differentiate between necrotic and health
myocardium tissues in case of cardiac events, for example myocardial infarction
[60].
Another focus of research in PVC is tumor imaging. PVC approaches are
used to improve lesions’ uptake in order to accurately delineating the metabolic
parts of a tumor and also to distinguish between healthy and cancerous cells [60].
2.4.5 Structural and Functional Information for Resolu-
tion Recovery (SFSRR)
In this project, the PVC method used was developed by Shidahara et al –
SFSRR (Structural and functional Information for Resolution Recovery) – and
consists in a wavelet-based resolution recovery method [32,67,68].
SFSRR is based on the Wavelet Transform (WT) which decomposes a signal
f(x) as a sum of translations (k) and dilations (j) into the spatio-frequency
domain. For achieving this objective, Multiresolution analysis (MRA) is used
which decomposes the signal f(x) through a high-pass filter ψ and a low-pass
filter ϕ [67, 68]:
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f(x) =
∑
k
J∑
j=1
dj(k).ψj.k(x) +
∑
k
Cj(k).ϕj.k(x) (2.12)
The elements of Equation 2.12 are:
• First and second terms represent, respectively, the high and low (residual)
frequency components of the image;
• dj(k) are the wavelet coefficients estimated by doing the inner (scalar)
product between the original signal and ψj.k orthonormal basis elements.
As a consequence, the numeric coefficients that characterize each element
of the original signal situated at the position k and in the j frequency
band (resolution level) are obtained;
• The high-pass function ψ is an orthonormal wavelet - Hilbert basis - as it
can be described by a family of functions ψj.k : j, kZ(orthonormal basis
elements) that characterize the multiples translations and dilations of ψ;
• Cj(k) are the scaling coefficients that represent the low frequency image
elements (residual).
The resolution recovery of PET images is done by using a priori anatomical
data which can be a CT or MRI image. The high frequency information present
in the structural data compensates the low morphological details of PET, guar-
anteeing an improvement in the existing anatomical aspects without affecting
the functional data.
The input data of this approach are:
• PET data - original PET data;
• Segmented PET data - the MRI or CT image is segmented and then for
each ROI is calculated the corresponding PET mean value;
• Smoothed Segmented PET data - Segmented PET data is smoothed by
applying a Gaussian filter.
SFSRR works according to three steps.
Firstly, PET, Segmented PET and Smoothed Segmented PET data are de-
composed by applying Equation 2.12. Consequently, wavelet coefficients for
each input data are estimated, respectively, dPETj , d
ana
j and d
anas
j .
Secondly, a weighted correlation of the wavelet coefficients is performed
based on three scaling factors [32,67,68]:
dcorrj (k, q) = βj(γj(αj .d
ana
j (k, q)) + (1− γj)dPETj (k, q)) (2.13)
where αj , γj and βj are the scaling parameters; q represents the quadrants
(directions) in which the image was decomposed.
Factor αj contemplates the intensity variances between PET and Segmented
PET data.
The second parameter γj evaluates if it is necessary to include structural
information to the current PET data.
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The recovery coefficient βj compares any spatial resolution differences be-
tween Segmented PET and Smoothed Segmented PET images. It is calculated
by doing the ratio between the wavelet coefficients from Segmented PET image
danaj and Smoothed Segmented PET image d
anas
j (smoothed with a 3D Guassian
filter in order to match PET’s resolution).
Finally, the estimated dcorrj (k, q) coefficients are applied to the original PET
image, resulting in an enhancement of its quality.
Figure 2.10: Representation of the SFSRR procedure.
2.5 PET/MRI nanoprobes studies
2.5.1 PET/MRI nanoprobes
In the last years, PET/MRI nanoprobes have become relevant because PET
and MRI are quite complementary techniques. PET has a really good sensitivity
for studying metabolic processes, but faces challenges in terms of spatial resolu-
tion and lack of morphological information. This can be overcomed by synergis-
tically combining PET to MRI which provides images with high-resolution and
anatomical information. Additionally, the nano-nature of these probes allows to
explore the existing internal volume for transporting and delivering imaging and
therapeutic substances to specific targets. Also, nanoparticles’ large surface area
gives the possibility of combining a wide variety of substances for monitoring
biological processes, imaging detection and evaluation of drug delivery.
Two studies have shown that nanoparticles are good contrast agents for
detecting lymph node metastases when using PET and MRI techniques, which
were performed by Choi et al (2008) [69] and Rafa et al (2011) [15].
Another area focus of interest in PET/MRI nanoprobes is cancer imaging.
Certain tumor cells have integrins in their membranes which are proteins com-
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posed of two glycoprotein chains called alpha α and β subunits. These integrins
expressed by tumour cells stimulate cell multiplication and migration. Based on
this aspect two scientific groups, Lee and coworkers (2008) [33] and Yang et al
(2011) [86], developed dual modality nanoprobes for evaluating their efficiency
in targeting in vivo tumor integrin αvβ3 expression cells.
Another type of tumor explored in PET/MRI nanoagents development was
glioblastoma, which is the most common brain tumor in humans. It affects
the glial cells present in the brain and spinal cord. Just one study involving
PET/MRI nanoparticles and glioblastomas was done by Luo et al (2012) [41].
Pancreatic cancer was also considered in PET/MRI nanoprobes development
by Locatelli et al (2012) [38], and more recently Kim et al [51] created a colon
tumor-targeting nanoagent in 2013.
Also, PET-MRI nanoprobes have been used in macrophage imaging for diag-
nosing atherosclerosis. This disease is characterized by the formation of plaques
within the arteries walls, resulting from the accumulation of fatty substances,
such as cholesterol and triglyceride, and calcium. The normal blood circula-
tion is affected, creating a thrombus and a chronic inflammatory response in
the affected area, activating macrophages and white blood cells towards the
atherosclerotic plaque. Therefore, in 2010 Jarret et al [29] and also by the
year of 2013 Majmudar and coworkers [45] created PET/MRI nanocarriers that
target monocytes and/or macrophages present in atherosclerotic plaques.
Finally, two more groups, Glaus and coworkers (2010) [23] and Sharma et
al (2013) [66] developed iron-oxide nanoparticles associated to PET isotopes in
order to evaluate their ability for being PET/MRI dual probes, i.e., verify any
changes in PET and MRI signals and respective activity uptake and/or contrast
in images.
2.5.2 PET/MRI nanoprobes and PVC
The study that lead to this project was done by Rosales et al [15] in 2011.
It consisted in developing a novel multimodal imaging agent with an iron oxide
core - MRI probe Endorem/Feridex (chemical formula Fe3O4) - associated to
124Cu isotope. PET-MR imaging studies were performed in a mouse to assess
the efficiency of these nanoagents for being taken by lymph nodes. MRI images
showed a decrease in T ∗2 contrast in regions where there was an accumulation
of nanoparticles, more specifically in popliteal and iliac lymph nodes, which
corresponded to a higher tracer’s uptake in PET images.
Until the present date no work has explored the potential of combining
PET/MRI nanoprobes and PVC procedures in order to improve the quality of
PET images, so this project is the first one developed on this area.
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Chapter 3
Materials and Methods
The materials and methods used in this thesis are referred in this chapter.
Firstly, the SFSRR procedure and its application to PET brain studies are
explained in Section 3.1.
Then, the method used for generating simulated data and corresponding
PVC performed are discussed in Section 3.2.
Finally, phantom data is described in detail in Section 3.3, giving emphasis to
the PET/MRI system used to acquire the data (Section 3.3.1), the experiments
done for defining an image processing protocol suitable for this dataset (Sections
3.3.3 and 3.3.4) and the PVC carried out in phantom data (Section 3.3.5).
3.1 SFSRR procedure - original processing pro-
tocol
SFSRR is a PVC procedure developed for PET brain studies. The program
has a graphical user interface and works according to five steps:
• Initialization;
• Co-registration;
• Segmentation;
• PET Brain Masking;
• PVC.
Firstly, original PET and MRI images are considered as input files in Ini-
tialization step. If both have distinct orientations, then flipping of data can be
performed. The output file(s) are automatically contemplated in the following
step.
In Co-registration step, PET image is registered into MRI native space.
Then, in order to perform the Segmentation step, a human brain atlas -
Hammerssmith atlas - is considered as an additional input [24]. Hammerssmith
atlas has 83 ROIs (regions-of-interest) that characterize distinct brain struc-
tures. Segmentation involves:
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1. Co-registration of the Hammerssmith atlas into MRI native space;
2. Segmentation of the MRI image;
3. For each anatomical region is assigned the regional PET mean value.
As a result, a Segmented PET atlas is created which contemplates the
anatomical features of the original MRI image and the average PET counts
for each ROI in co-registered PET data.
In Masking step, a brain mask is applied to the original PET image so that
the counts located outside the brain are set to zero. The resulting file is called
Masked PET data.
Finally, Segmented PET atlas and Masked PET data are the input files of
the PVC step which requires:
1. Reslice Segmented PET atlas into PET space;
2. Segmented PET atlas is smoothed by using a Gaussian filter and a new
dataset named Smoothed Segmented PET data is created;
3. PVC is performed taking into account Masked PET data, Segmented PET
atlas and Smoothed Segmented PET data.
Figure 3.1: Overview of SFSRR steps. [54]
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3.2 Simulated Data
A simple experiment using simulated data was performed in order to under-
stand how the SFSRR procedure works.
3.2.1 Data creation
Simulated data was created in MATLAB in a total of four datasets:
• True data;
• PET data;
• Segmented PET data;
• Smoothed Segmented PET data.
It was chosen that simulated data would have 200x200x8 as dimensions and
0.25x0.25x1 mm3 as voxel size which corresponds to phantom data features.
3.2.1.1 True data
True data aims to recreate the original features of a square object without
the blurring caused by PET low spatial resolution. For this purpose, True data
was generated so that in the centre there was a square which voxels had the
same intensity 1000 while outside were 0. This premise was considered in all
eight slices (Figure 3.2).
3.2.1.2 PET data
PET data was produced by applying a 2D Gaussian filter (FWHM=2mm)
to True data. This FWHM value was used to guarantee the existence of at least
20% of PVEs, more specifically True data has 1000 as maximum and PET data
should not have more than 800 as maximum.
PET image = True image⊗Gaussian filter (3.1)
All data slices were created according to this methodology. The resulting
data is shown in Figure 3.2.
3.2.1.3 Segmented PET data
Segmented PET data was originated by changing square’s voxels values by
the regional PET mean value (Figure 3.2). The mean value obtained was 503.3.
3.2.1.4 Smoothed Segmented PET data
Finally, Smoothed Segmented PET data was created by convolving Segmented
PET data with a 1.5mm 2D Gaussian filter.
Smoothed Segmented PET data = Segmented PET data⊗Gaussian filter
(3.2)
Smoothed Segmented PET data is shown in Figure 3.2.
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Figure 3.2: Top to bottom, from left to right: True, PET, Segmented PET and Smoothed Segmented PET datasets.
3.2.1.5 Convert data into int16 datatype and Analyze format
SFSRR method has the following requirements in terms of:
• Datatype
– Int16 [−32768, 32767];
– Int 32 [−2147483648, 2147483647];
– Double [−10308, 10308].
• Format
– Analyze;
– Nifti.
In this context, all datasets were converted into int16 and then imported
from MATLAB [48] into Fiji software [63], through Miji plugin [61], so that
they could be saved in Analyze format.
3.2.2 Partial Volume Correction using SFSRR procedure
PVC of simulated data was performed by using SFSRR procedure. In this
case, as the data was already processed, i.e. the usual steps – Initialization,
Co-registration, PET Brain Masking and Segmentation - were not required and
so just the SFSRR mod script was used.
This script is responsible for applying the SFSRR procedure into PET data
and it uses three input files:
• PET data;
• Segmented PET data;
• Smoothed Segmented PET data.
Input data Intensity Range [Bq/ml]
PET [0,800]
Segmented PET [0,503]
Smoothed Segmented PET [0,498]
Table 3.1: Intensity range for different SFSRR input data: PET, Segment PET
and Smoothed PET.
The output file is a new PET dataset - Corrected PET data (Table 3.2).
Recovered data Intensity Range [Bq/ml]
Corrected data [-146,976]
Table 3.2: Intensity range for Corrected data.
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Figure 3.3: Corrected PET data.
3.3 Phantom Data
3.3.1 Mediso nanoScan PET/MRI scanner
The phantom data used in this project was obtained through a partnership
between King’s College London and Karolinska Institutet.
The images were acquired in a combined Mediso nanoScan PET-MRI imag-
ing scanner in Karolinska Institutet (Figure 3.4).
Figure 3.4: Mediso nanoScan PET/MRI scanner [74].
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The MRI system accommodates an 1 Tesla permanent magnet, a gradient
coil and a radiofrequency (RF) shielding that protects PET electronics compo-
nents from the main magnetic field and gradients. MRI images can achieve a
spatial resolution of 100 µm (microns).
On the other hand, the PET module consists of an array of LSO scintillation
detectors and can originate data up to 700 µm of spatial resolution.
3.3.2 Data
The main goals for using phantom data were:
1. determine how the object size influences PVC;
2. performance of the SFSRR procedure when applying it to phantom data
containing different nanoparticles and 18F solutions;
3. how the smoothing affects the resolution recovery performed.
For this purpose, a Cucumis sativus was used as phantom due to its high
water content and so it is quite distinguishable in MRI. Inside, it had twelve
tubes with different diameters in order to explore the effect of the object size in
PVC. Three different cylindrical tubes were used:
• Small tube (0.5 mm in diameter);
• Medium tube (1 mm in diameter);
• Big tube (1.5 mm in diameter);
All tubes were filled with solutions containing distinct concentrations of
SPIO nanoparticles associated to Fluorine-18, except two tubes that had water
to be used as reference (Figure 3.5). Therefore, it was possible to study the
effect of nanoparticles and 18F concentrations in the recovery performed.
Solution Constituents
Nanoparticles
Concentration
[mgFe/mL]
18F Activity
[Bq/ml]
A SPIOs and 18F 0.02500 4.32× 107
B SPIOs and 18F 0.01250 2.16× 107
C SPIOs and 18F 0.00625 1.08× 107
Water Water 0.00000 0.00× 107
Table 3.3: Nanoparticles and tracer concentrations evaluated in phantom data.
The influence of smoothing in the SFSRR procedure was analysed by con-
sidering different Smoothed Segmented PET datasets as one of the input files of
this PVC approach. This aspect is described in more detail in Section 3.3.5.
Data was acquired by performing a simultaneous 63 min PET-MRI scan.
T2-weighted MRI images were acquired to explore the T2 contrast ability of
SPIO nanoparticles, enabling to determine the exact location of the tubes in
Cucumis sativus.
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In terms of PET data, a static dataset was acquired and reconstructed using
3D adjMC method which employs an iterative maximum likelihood estimation
method (ML-EM/OSEM) associated to an Adjoint Monte Carlo approximation
(adjMC) [43].
Figure 3.5: Solutions and corresponding tubes present in Cucumis sativus.
Parameters Description
Iterations 20
Subset 1
Energy Window 400-600 keV
Table 3.4: Parameters used in PET data reconstruction.
3.3.3 Experiments for defining an Image Processing pro-
tocol
3.3.3.1 Original phantom data features
The image processing protocol that comes with the SFSRR procedure is
just applicable to PET brain images. Therefore, an image processing protocol
suitable for phantom data had to be developed.
For this purpose, the requirements of the SFSRR methodology were consid-
ered:
• Images - 3D static PET images and CT/MRI anatomical images can be
used;
• Datatype
– Int16 [−32768, 32767];
– Int 32 [−2147483648, 2147483647];
– Double [−10308, 10308].
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• Format
– Analyze;
– Nifti.
The features of PET and MRI original datasets are shown in Tables 3.5 and
3.6.
Modality Description
MRI
Dimensions 200x200x8
Voxel size 0.25x0.25x1 (mm3)
Intensity range [0,145997]
Datatype Unsigned short 16 (uint16)
Scaling factor SM = 35.652500
File format DICOM
Table 3.5: MRI data features.
Modality Description
PET
Dimensions 200x200x200
Voxel size 0.25x0.25x0.25 (mm3)
Intensity range [0,4.12x107] (Units: Bq/ml)
Datatype Unsigned short 16 (uint16)
Scaling factor SP = 628.206604
File format DICOM
Table 3.6: PET data features.
PET and MRI data are represented according to unsigned short 16 bits
(uint16) datatype which intensity range is [0, 65535], however in both cases
their maximum intensity goes beyond the uint16 maximum value:
• MRI - [0, 145997];
• PET - [0, 4.12× 107].
This occurs because a scaling factor multiplying with the different intensity
values was used:
S ∗ [a, b] (3.3)
where S is the scaling factor, a and b are the minimum and maximum values,
respectively.
Modality No scaling factor Considering scaling factor
PET [0, 216]↔ [0, 65536] 628.206604 ∗ [0, 65536]↔ [0, 4.12× 107]
MRI [0, 212]↔ [0, 4096] 35.652500 ∗ [0, 4096]↔ [0, 145997]
Table 3.7: Intensity range of PET and MRI in absence or not of a scaling factor.
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3.3.3.2 SPM
The first software evaluated for defining an image processing protocol was
SPM (Statistical Parametric Mapping) [22].
In SPM, phantom data processing was done according to the following steps:
1. Convert data from DICOM to Analyze format;
2. Data reorientation;
3. Coregistration.
Most scanners save data in DICOM format, where there is one file per slice
(and per timepoint in case of dynamic data). So, firstly PET and MRI data
were converted into Analyze format.
Then, as MRI and PET datasets had different orientations (Figure 3.6),
PET data was flipped 180 degrees according the y-axis. The resulting data is
shown in Figure 3.7.
In spite of flipping PET data, MRI and PET datasets were still not perfectly
overlaid (Figure 3.7), so translations in PET data needed to be done. However,
PET and MRI data had distinct dimensions and voxel size and so they could
not be loaded at the same time, so translations done in phantom data could
lead to errors. Therefore, another software called AMIDE was evaluated for
processing the data.
Figure 3.6: Left: Original MRI data in SPM. Right: Original PET data in SPM.
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Figure 3.7: Left: Original MRI data in SPM. Right: Flipped PET data in SPM.
3.3.3.3 AMIDE
AMIDE is a free software for analyzing and registering medical imaging
datasets [39].
First of all, PET and MRI images were loaded into AMIDE (Figure 3.8).
Figure 3.8: Images load into AMIDE software. Top: MRI original data; Bottom:
PET original data.
Both datasets are not perfectly overlaid, so manual corrections were per-
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formed:
• Change data centers;
• Reorientation;
• Translations.
PET and MRI data centers were changed to: (i) x=0 mm; (ii) y=0 mm and
(iii) z=0 mm.
Modality Initial data center New data center
MRI
x: −225.00 mm x: 0.00 mm
y: 275.00 mm y: 0.00 mm
z: −0.50 mm z: 0.00 mm
Table 3.8: MRI data centers.
Modality Initial data center New data center
PET
x: −1.88 mm x: 0.00 mm
y: −5.13 mm y: 0.00 mm
z: −119.18 mm z: 0.00 mm
Table 3.9: PET data centers.
The following step consisted in flipping PET data 180 degrees according the
y-axis so that it has the same orientation as MRI data.
Then, PET data was submitted to two translations:
• x: -2.0 mm;
• y: 5.6 mm.
Figure 3.9 shows PET and MRI data after performing these changes.
The last step consisted in registering data. PET and MRI data have distinct
dimensions and voxel size: MRI dimensions are 200x200x8 and voxel size is
0.25x0.25x1 mm3, while in PET are respectively 200x200x8 and 0.25x0.25x0.25
mm3. For these conditions, AMIDE automatically registered PET data to a
voxel size of 0.25x0.25x1 mm3 and 208x223x50 as dimensions. However, since
we would like PET data to have the same dimensions as MRI data, we decided
to use another software for processing phantom data.
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Figure 3.9: MRI and PET data after transformations.
3.3.4 Final Image Processing protocol
After the previous trials, it was chosen that MRI and PET data would be
processed by using the following softwares:
• VivoQuant [28];
• Fiji [63];
• MATLAB [48].
The processing approach selected will be explained in more detail in the
following subsections.
3.3.4.1 VivoQuant
VivoQuant is inviCRO’s multi-modality post-processing software which can
be used for SPECT, CT, PET, MR and optical imaging data [28].
This software was selected for reorienting the data and performing image
registration, because data reslice and resample in VivoQuant are performed
automatically without requiring user intervention.
First of all, PET and MRI original data were imported into VivoQuant. The
intensity range of PET data changed because VivoQuant automatically modifies
the voxel size and dimensions of PET data so that it matches the features of
the reference image, in this case the MRI dataset, which are 200x200x8 as
dimensions and 0.25x0.25x1 mm3 as voxel size. The new intensity values of
PET and MRI data are shown in Tables 3.10 and 3.11.
38
PET original data New PET data
[0,4.12× 107] [0,3.58× 107]
Table 3.10: PET intensity values.
MRI original data New MRI data
[0,145997] [0.005,145997]
Table 3.11: MRI intensity values.
MRI and PET images have different orientations (Figure 3.10).
Figure 3.10: Initial orientation of PET and MRI data.
MRI data was reoriented 180 degrees in the x-axis direction. On the other
hand, PET images were flipped 180 degrees in the y-axis direction.
Even after flipping, PET and MRI images were not perfectly overlaid (Figure
3.11).
So, PET data was manually corrected by using the following translation
values:
• Translation x-axis: -2.0 mm;
• Translation y-axis: -5.6 mm.
The result obtained is displayed in Figure 3.12.
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Figure 3.11: MRI and PET dat after flipping.
Figure 3.12: MRI and PET data after translation.
It is important that after the processing steps, MRI and PET have the same
format and datatype.
Related with the data format, it was chosen to export the images in Raw
format because when saving as DICOM format in VivoQuant this software locks
certain features of the images, which then are not detectable by other imaging
softwares.
In terms of datatype, single-precision 32-bit floating-point representation,
float32 [10−38, 1038] was considered for describing more accurately the intensity
values of the data without requiring the use of scaling factors as it happened in
the original data (Table 3.7).
Table 3.12 shows the new features of MRI and PET datasets.
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Modality Description
MRI
Intensity Range [0,145997]
Datatype Float32
File format Raw
PET
Intensity Range [0,3.58x107]
Datatype Float32
File format Raw
Table 3.12: MRI and PET new data features.
3.3.4.2 Fiji
Fiji is a distribution of ImageJ that allows performing image processing and
data analysis [63].
MRI data in Raw format was opened in Fiji and ROIs corresponding to the
location of the different tubes were drawn. The same strategy was applied to
all eight slices and therefore eight ROI maps were created.
3.3.4.3 MATLAB
MATLAB is a programming language and software which can be applied to
analyse data, create algorithms and models, as well as to develop other appli-
cations [48].
PET Masking
In PET data is not possible to distinguish the exact location of all tubes.
Consequently, ROI maps generated with Fiji were imported into MATLAB by
using MIJ plugin which allows exchange data between these two softwares.
These maps were used to mask Registered PET data, originating Masked
PET data (Figure 3.13).
ROIs and Mean
The aim of ROIs and Mean step was to assess each tube ROI and then
change their voxels values by the regional PET mean value, resulting in Seg-
mented PET data (Figure 3.13).
Smoothing
The final dataset created was Smoothed Segmented PET data which is orig-
inated by convolving Segmented PET data with a 2D Gaussian filter.
Smoothed Segmented PET data = Segmented PET data⊗Gaussian filter
(3.4)
Different values of FWHM were used in order to evaluate how the smoothing
affects the efficiency of the SFSRR procedure. As real data has 200x200x8 as
dimensions and 0.25x0.25x1 mm3 of voxel size, the FWHM values chosen were:
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• 0.8 mm;
• 1 mm;
• 1.2 mm;
• 1.4 mm.
In total, four Smoothed Segmented PET datasets were created which have
the following denominations (Figure 3.13):
• S1 - Smoothed Segmented PET dataset obtained when using a Gaussian
filter with FWHM=0.8mm;
• S2 - Smoothed Segmented PET dataset originated by applying a Gaussian
filter with FWHM=1mm;;
• S3 - Smoothed Segmented PET dataset created with a Gaussian filter that
has FWHM=1.2mm;
• S4 - Smoothed Segmented PET dataset generated when using a Gaussian
filter that has FWHM=1.4mm.
Export data
In SFSRR procedure, data must obey to the following requirements:
• Datatype
– int16 which range of values is [−32768, 32767];
– in32 with [−2147483648, 2147483647];
– double that has the following values interval [−10308, 10308].
• Format
– Analyze;
– Nifti.
Thus, Masked PET, Segmented PET and Smoothed Segmented PET datasets
were exported from MATLAB in Analyze format and double datatype to comply
with SFSRR requirements.
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Figure 3.13: Top to bottom, from left to right: True, PET, Segmented PET and Smoothed Segmented PET datasets.
3.3.5 Partial Volume Correction using SFSRR procedure
Partial volume correction of the real data was performed by using the SFSRR
procedure, more specifically the SFSRR mod script, as the data was already
processed, and so it was not required to do the usual steps – Initialization,
Co-registration, PET Brain Masking and Segmentation.
Three input files were used (Table 3.13):
• PET data;
• Segmented PET data;
• Smoothed Segmented PET data.
As in total four Smoothed Segmented PET datasets - S1, S2, S3 and S4 -
were created in order to assess the efficiency of the SFSRR, the procedure was
applied four times.
Input data Intensity range [Bq/ml]
PET [0,3.58×107]
Segmented PET [0,1.39×107]
S1 [0,1.38×107]
S2 [0,1.32×107]
S3 [0,1.16×107]
S4 [0,1.01×107]
Table 3.13: Input data and Corrected PET datasets 1 to 4, which correspond
to the recovery data when using, respectively, S1 to S6 as Smoothed Segmented
PET data.
The output file of the SFRSS approach is a new PET image (Corrected PET
data).
Table 3.14 shows the intensity ranges of Corrected PET datasets.
Recovered data Intensity range [Bq/ml]
Corrected PET data 1 [-1.13×107,5.53×107]
Corrected PET data 2 [-1.53×107,6.31×107]
Corrected PET data 3 [-1.88×107,6.99×107]
Corrected PET data 4 [-2.28×107,7.74×107]
Table 3.14: Corrected PET datasets 1 to 4, which correspond to the recovery
data when using, respectively, S1 to S4 as Smoothed Segmented PET data.
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Chapter 4
Results and Discussion
4.1 Simulated data
4.1.1 Intensity Range
True, simulated, segmented, smoothed and recovered images are shown in
Figure 4.1. There are differences between PET data and Corrected PET data
upon visual inspection. This becomes more clear when observing Table 4.1, as
the minimum value changed from 0 to -146 and the maximum value changed
from 800 to 976.
Simulated data Intensity Range [Bq/ml]
True data [0,1000]
PET data [0,800]
Segmented PET data [0,503]
Smoothed Segmented PET data [0,498]
Corrected PET data [-146,976]
Table 4.1: Intensity ranges of simulated data.
In order to assess the location of the negative values, two regions - back-
ground and object - were defined in PET and Corrected PET data and the cor-
responding minimum, maximum and mean values were estimated (Table 4.2).
Dataset Region Slices
Min
[Bq/ml]
Max
[Bq/ml]
Mean ± S.D.
[Bq/ml]
PET data
Object 1 to 8 277.0 800.0 503.3 ± 155.7
Background 0.0 0.0 0.0 ± 0.0
Corrected data
Object 1 to 8 406.5 850.5 557.4 ± 122.7
Background -117.8 23.4 -0.1 ± 3.4
Table 4.2: Minimum, maximum and mean values of the regions identified in
PET and Corrected data.
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Figure 4.1: Simulated images (Top to bottom, from left to right): True data, PET data, Segmented PET data; (bottom, from left to
right) Smoothed Segmented PET data and Corrected PET data obtained with SFSRR method.
The negative values detected in Corrected PET data are located in the back-
ground and in the boundary between this region and the object (Figure 4.2).
This might be related with the difficulty of the wavelet transform in decompos-
ing circular objects. However, this aspect does not compromise the resolution
recovery performed, as the important PET counts are located inside the object
and not in the surrounding areas.
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Figure 4.2: Zoomed images. Left: PET data; Right: Corrected PET data.
4.1.2 Intensity differences in the different slices
True, PET, Segmented PET and Smoothed Segmented PET datasets were
created so that all the 8 slices would be equal, i.e., would have the same intensity
features, but it did not occur after performing PVC when analysing Corrected
PET data. This aspect can be seen in more detail in Figure 4.3 which shows
the transverse and coronal views of PET and Corrected PET datasets, as well
as in the line profiles defined in both datasets (Figure 4.4).
The expected results would be that all slices of Corrected PET data had
the same intensity values considering the initial conditions of input data - PET,
Segmented PET and Smoothed Segmented PET datasets - however this did not
happen. Therefore, further studies in this regard are necessary.
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Figure 4.3: Transverse and Coronal views of PET and Corrected PET datasets.
1 2 3 4 5 6 7 8
750
800
850
900
950
1000
Line profiles
Distance (mm)
In
te
ns
ity
 
 
PET data profile
Corrected PET data profile
Figure 4.4: Line profiles from PET and Corrected PET datasets.
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4.1.3 Partial Volume Correction
For checking the changes introduced by the SFSRR method, the maximum
and mean values from PET and Corrected PET datasets were calculated (Ta-
bles A.1 and A.2). The Difference between recovered values in Corrected PET
data and the original values in PET data was estimated by using the following
expression:
Difference =
[(
recovered value
original value
)
− 1
]
× 100% (4.1)
Certain slices showed an increase in terms of the maximum values, more
specifically between 0.8% and 22.0%. The maximum values in Slices 1 and 8 of
Corrected PET data, respectively 976 and 965, did not differ significantly from
the intensity of True data which was 1000. Thus, a better recovery was achieved
in these slices, 22.0% and 20.6%. On the other hand, other slices showed a small
decrease in the maximum values of around -2.0% (Figure 4.5 and Table A.1 in
Appendix A).
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Figure 4.5: Maximum values in each slice of PET and Corrected PET datasets.
Relating to the mean values, increases were verified in the majority of the
slices (Figure 4.6 and Table A.2 in Appendix A), but a slight decrease was
observed in Slices 4 and 5, respectively, -0.5% and -1.2%.
As mentioned previously in Section 4.1.2, a non-uniformity in the intensities
was verified in Corrected PET data, so the differences displayed in Figures 4.5
and 4.6 and Tables A.1 to A.2 (Appendix A) are in concordance with this aspect.
In general, the use of the SFSRR procedure translated into a global improve-
ment of the activity, respectively, 6.8 % and 10.3% in the maximum and mean
values.
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Figure 4.6: Mean values in each slice of PET and Corrected PET datasets.
4.2 Phantom data
4.2.1 Intensity Range
PET and Corrected PET datasets are shown in Figure 4.7 and differences
are noticeable by visual inspection.
Table 4.3 displays the intensity ranges from PET and Corrected PET data.
Firstly, lower minimum values were detected in Corrected PET data 3 and
4 where a more significant smoothing was applied to one of the input data -
Smoothed Segmented PET. On the other hand, the maximum values increased
after performing PVC.
Phantom data Intensity Range [Bq/ml]
PET data [0.00×107,3.58×107]
Corrected PET data 1 [-1.13×107,5.53×107]
Corrected PET data 2 [-1.53×107,6.31×107]
Corrected PET data 3 [-1.88×107,6.99×107]
Corrected PET data 4 [-2.28×107,7.74×107]
Table 4.3: Intensity ranges of PET and Corrected data. Corrected PET datasets
differ in terms of the data used as Smoothed Segmented PET data in the SFSRR
procedure: (i) in Corrected PET data 1 was S1; (ii) in Corrected PET data 2
was S2; (iii) in Corrected PET data 3 was S3 and (iv) in Corrected PET data
4 was S4.
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Figure 4.7: Phantom data. Top to bottom, from left to right: PET and Corrected PET data 1 to 4.
The negative values detected in Corrected PET are located in the boundary
between the tubes and the background (Figure 4.8). This aspect was also visible
in the simulated data and it might be related with the limitation of the wavelet
transform at decomposing circular objects.
This situation does not compromise the resolution recovery performed as the
relevant measurements are located inside the tubes and not in the boundary and
background areas.
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Figure 4.8: Zoomed images of Corrected PET datsets for displaying the location
of the negative values.
4.2.2 Partial Volume Correction
The maximum and mean values of the tubes containing SPIOs nanoparticles
and 18F were estimated for PET and Correced PET datasets. The units used
were kBq/ml instead of Bq/ml in order to show more clearly the results obtained.
The changes introduced by the SFSRR procedure were assessed by estimat-
ing the Difference factor (Equation 4.1.3).
Figures 4.9 and 4.10 display the different tubes used in phantom data, while
Table 4.4 shows the solutions evaluated.
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Figure 4.9: Tubes identification.
Figure 4.10: Solutions and corresponding tubes present in Cucumis sativus.
Solution Constituents
Nanoparticles
Concentration
[mgFe/mL]
18F Activity
[kBq/ml]
A SPIOs and 18F 0.02500 4.32× 104
B SPIOs and 18F 0.01250 2.16× 104
C SPIOs and 18F 0.00625 1.08× 104
Water Water 0.00000 0.00× 104
Table 4.4: Nanoparticles and tracer concentrations evaluated in phantom data.
The maximum values are shown in Figures 4.11 and Table B.1 (Appendix
B).
The SFSRR procedure led to an increase in the maximum values of all tubes.
Higher recovery deviations were detected in small tubes and containing a higher
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concentration of nanoparticles and Fluorine-18.
Small tubes 1 and 2 with solution A, that had a higher concentration of
nanoparticles and tracer, showed an average increase of 95.6 %, 128.8 %, 156.7%
and 187.4% for Corrected PET data 1 to 4.
The second higher difference corresponded to small tubes 3 and 4 with solu-
tion C, lower content of nanoparticles and Fluorine-18, with average increases
of 81.0%, 108.6%, 131.8% and 157.2% for Corrected PET data 1 to 4.
In medium tubes, a higher concentration of radioisotope and nanoparticles
resulted in a larger recovery, around 101.0%, when comparing to solutions B
and C that showed average improvements of 98.9% and 94.8%.
In contrast, higher differences in maximum values were obtained for smaller
concentrations of nanoparticles and 18F in big tubes. Tube 5 containing solution
A had an average increase of 85.3%, while tubes 7 and 10 with solutions B and
C showed a recovery of 87.4% and 101.2%.
Additionally, the mean values and the corresponding Difference factors were
estimated in PET and Corrected PET datasets (Figure 4.12 as well as Tables
B.3 and B.4 in Appendix B).
An increase in the mean values was observed in all tubes with this aspect
being progressively more significant for higher smoothing values.
In order to better understand the changes in the tracer’s uptake after per-
forming PVC, the Differences calculated and shown in Table B.4 were organized
so that three aspects could be evaluated:
• how the object size influences PVC (Section 4.2.2.1);
• performance of SFSRR procedure when applying it to phantom data with
distinct concentrations of nanoparticles and Fluorine-18 (Section 4.2.2.1);
• how smoothing affects the resolution recovery performed (Section 4.2.2.2).
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Figure 4.11: Maximum values in PET and Corrected PET datasets: Solution A - Tubes 1, 2, 6 and 5; Solution B - Tubes 8 and 7; Solution
C - Tubes 3, 4, 9 and 10.
Small tube 1 Small tube 2 Medium tube 6 Big tube 5 Medium tube 8 Big tube 7 Small tube 3 Small tube 4 Medium tube 9 Big tube 10
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
x 104 Differences in the Mean intensity
I
n
t
e
n
s
i
t
y
 
[
k
B
q
/
m
l
]
 
 
PET
Corrected PET 1
Corrected PET 2
Corrected PET 3
Corrected PET 4
Figure 4.12: Mean values in PET and Corrected PET datasets: Solution A - Tubes 1, 2, 6 and 5; Solution B - Tubes 8 and 7; Solution C
- Tubes 3, 4, 9 and 10..
4.2.2.1 Influence of the object size and nanoparticles concentrations
in PVC
The influence of the object size in PVC was studied by using three different
cylindrical tubes in phantom data:
• Small tube (0.5 mm in diameter);
• Medium tube (1 mm in diameter);
• Big tube (1.5 mm in diameter).
Additionally, for each tube two or more solutions were used in order to
evaluate how the PVC is related with the nanoparticles and 18F concentrations
considered (Table 4.4).
The Difference factors in Table B.4 (Appendix B) were organized to show
how the resolution recovery was affected by the tubes size (Figure 4.13) and
nanoparticles-18F solutions (Figure 4.14).
The use of small tubes and solution A provided mean improvements within
[51.0;113.5] % for the different smoothing values, while for the same object
size but with a lower concentration of nanoparticles and 18F (solution C) the
differences observed were between 45.2 and 104.0 %.
On the other hand, greater changes in medium tubes were achieved when
considering progressively a smaller concentration of nanoparticles and 18F:
• Solution A - [35.4;74.3] %;
• Solution B - [37.2;75.5] %;
• Solution C - [39.5;82.6] %;
Big tubes also showed the same variation pattern than in medium tubes.
Higher variations in recovery were observed when gradually a lower concentra-
tion of nanoprobes was used, however they were not so high as in medium size
objects:
• Solution A - [24.7;46.5] %;
• Solution B - [26.1;50.1] %;
• Solution C - [34.2;71.7] %;
Smaller objects tend to be more affected by PVEs, resulting in a more signifi-
cant blurring of the object’s activity to neighbour areas and consequently greater
underestimation of tracer’s uptake. In this case, SFSRR originated larger vari-
ations in quantification for smaller tubes size when comparing to medium and
big tubes.
In terms of the solutions evaluated, greater recovery differences in the small
tubes were detected for higher concentrations of nanoparticles and 18F. In con-
trast, PVC showed higher improvements for a lower concentration of SPIO
nanoparticles and 18F in medium and big tubes, however this aspect was more
significant in medium tubes than in the big tubes.
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4.2.2.2 Smoothing versus recovery
The Differences calculated (Table B.4) were used for assessing the effect of
smoothing in resolution-recovery (Figure 4.15).
Higher smoothed FWHM values led to poorer spatial resolution of Smoothed
Segmented PET data and for these conditions SFSRR originated greater im-
provements in all tubes.
This aspect resulted from the fixed resolution levels j considered by the
method (Equation 2.12). More specifically, currently SFSRR uses fixed fre-
quency bands for decomposing the input data which may not be ideal for the
phantom data used in this project. Therefore, further experiments are required
for verifying which resolution levels j are suitable for this specific data as well as
to better understand how smoothing really influences the recovery performed.
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Figure 4.13: Measured Differences for solutions A, B, C and water depending on the tube size and the smoothing values used.
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Figure 4.14: Differences estimated for different nanoparticles solutions and smoothing values.
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Figure 4.15: The relationship between image smoothing (FWHM in mm) and % difference of the tracer’s uptake in the different tubes
and solutions.
Chapter 5
Conclusion
One of the goals of this project consisted in performing a simple simulation
study in order to understand how the SFSRR procedure works. In general,
the use of SFSRR procedure translated into uptake improvements of 6.8 % in
maximum values and 10.3% in mean values. Simulated data was created so
that all slices had the same intensity, however recovered data did not show this
uniformity as expected. As a result, this aspect will be clarified in future work.
Additionally, the second part of the work focused on developing an image
processing protocol suitable to phantom data and then perform PVC by using
the SFSRR procedure.
For this purpose, firstly SPM was evaluated for data processing. As PET
and MRI data had distinct dimensions and voxel size, both datasets could not
be loaded at the same time in SPM and so any translations done would lead to
errors. Therefore, another processing strategy was assessed.
The second software used was AMIDE which allows to reorient and resample
data, as well as to perform manual transformations. However, data reslice
cannot be done according to the user requirements and as in this case PET
data should have the same features than MRI, AMIDE was not selected for
data processing.
In terms of the final Image Processing Protocol defined the following soft-
wares were used: (i) VivoQuant; (ii) Fiji and (iii) MATLAB.
VivoQuant automatically performs data resampling and reslice. Also, it
allows to reorient data and perform translations with PET and MRI datasets
overlaid at the same time, minimizing any errors related with user intervention.
On the other hand, Fiji was used to create the ROI maps as it has a wide
variety of shapes and tools for drawing ROIs. Another advantage is the MIJ
plugin that allows a bidirectional communication between Fiji and MATLAB,
guaranteeing an easy and accurate way to read and exchange data between these
two softwares.
Finally, MATLAB was used to perform: (i) PET masking; (ii) estimate
the mean values in the different tubes; (iii) filtering and to (iv) export data in
Analyze format and double datatype.
The third and last part of this project consisted in evaluating how object
size, SPIOs-18F concentrations and smoothing affected PVC in phantom data
when using the SFSRR procedure.
PVEs are more significant in smaller object sizes and for greater smoothed
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values. Phantom data results showed greater uptake differences when using
small tubes, higher concentrations of SPIOs-18F and greater smoothing values.
Also, higher uptake deviations were verified in medium and big tubes for lower
solutions’ concentrations and greater FWHM values.
The results obtained showed that the SFSRR procedure is efficient for mini-
mizing the influence of PVEs in PET images, however the SFSRR package was
developed to be used in brain PET images and so the parameters of the recovery
model are optimized for this purpose. Therefore, several parameters will have
to be changed for adapting this methodology to phantom data which will be
focus of future work. Additionally, further experiments will be done in order to
better understand these initial results.
To extend on the work undertaken in this thesis, it would be important to
perform more simulation studies that aim to recreate certain factors that affect
PET images quality and check how they affect SFSRR efficiency:
• Attenuation;
• Noise;
• Smoothing effect - the SFSRR procedure requires the use of a Gaussian
filter, so different values of FWHM could be considered.
After simulations studies, phantom data analysis could be done. More specif-
ically, it would be relevant to create an unique phantom that could be applied in
all future experiments to guarantee a standard approach of data acquisition and
processing. This would minimize any potential errors occurring during these two
steps.
The phantom could consist in an inert medium with different holes that
would recreate different object sizes, as this is one of the aspects that contributes
to PVES. Then, inside of each hole different concentrations of nanoparticles
associated to PET radioisotopes could be used to recreate the spill-over effect,
that generally is more significant for smaller objects.
Also, it would be interesting to use distinct kinds of nanoparticles and PET
radioisotopes in order to understand how they would influence the efficiency of
the PVC performed.
Finally, besides exploring the recovery performed by the SFSRR procedure,
other PVC methodologies could be studied, for example Lucy-Richardson decon-
volution algorithm, van Cittert method and GTM (Geometrix Transfer Matix)
approach, which are the most common PVC routines.
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Appendix A
Simulated data - Results
Dataset Region Slice Max [Bq/ml] Difference [%]
True Object 1 to 8 1000.0 -
PET Object 1 to 8 800.0 -
Corrected PET
Object 1 976.0 22.0
2 844.0 5.5
3 798.0 -0.2
4 784.0 -2.0
5 780.0 -2.5
6 806.0 0.8
7 851.0 6.4
8 965.0 20.6
Table A.1: Maximum values in PET and Corrected PET data and corresponding
difference (%).
Dataset Region Slice
Mean±S.D.
[Bq/ml]
Difference [%]
True Object 1 to 8 1000.0 ± 0.0 -
PET Object 1 to 8 503.3 ± 155.7 -
Corrected PET
Object 1 652.5 ± 148.3 29.6
2 558.2 ± 119.5 10.9
3 518.2 ± 111.9 3.0
4 500.7 ± 111.0 -0.5
5 497.4 ± 110.3 -1.2
6 524.6 ± 113.2 4.2
7 564.9 ± 120.7 12.2
8 642.9 ± 146.4 27.7
Table A.2: Mean values in PET and Corrected PET data and corresponding
difference (%) between both datasets.
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Appendix B
Phantom data - Results
Solution A Solution B
Dataset Small Small Medium Big Medium Big
tube 1 tube 2 tube 6 tube 5 tube 8 tube 7
PET 12689.7 11767.5 21873.1 35847.9 8624,0 16149.7
Corrected PET 1
(FWHM=0,8mm)
24816.0 23010.4 35812.7 55300.7 13969.5 25059.1
Corrected PET 2
(FWHM=1,0mm)
29040.0 26908.4 41462.7 63099.1 16160.7 28650.4
Corrected PET 3
(FWHM=1,2mm)
32597.4 30184.6 46436.2 69847.2 18086.6 31844.1
Corrected PET 4
(FWHM=1,4mm)
36511.9 33783.8 52106.3 77438.4 20386.9 35487.6
Solution C
Dataset Small Small Medium Big
tube 3 tube 4 tube 9 tube 10
PET 1241.1 1037.4 2157.7 8646.6
Corrected PET 1
(FWHM=0,8mm)
2136.2 1970.0 3478.9 14099.0
Corrected PET 2
(FWHM=1,0mm)
2483.4 2252.7 4020.6 16352.2
Corrected PET 3
(FWHM=1,2mm)
2799.7 2468.8 4437.4 18385.0
Corrected PET 4
(FWHM=1,4mm)
3169.7 2686.4 4876.6 20745.7
Table B.1: Maximum values in kBq/ml of the tubes present in PET and Cor-
rected PET data.
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Solution A Solution B Solution C
Dataset Small Small Medium Big Medium Big Small Small Medium Big
tube 1 tube 2 tube 6 tube 5 tube 8 tube 7 tube 3 tube 4 tube 9 tube 10
PET — — — — — — — — — —
Corrected PET 1
(FWHM=0,8mm)
95.6% 95.5% 63.7% 54.3% 62.0% 55.2% 72.1% 89.9% 61.2% 63.1%
Corrected PET 2
(FWHM=1,0mm)
128.8% 128.7% 89.6% 76.0% 87.4% 77.4% 100.1% 117.1% 86.3% 89.1%
Corrected PET 3
(FWHM=1,2mm)
156.9% 156.5% 112.3% 94.8% 109.7% 97.2% 125.6% 138.0% 105.7% 112.6%
Corrected PET 4
(FWHM=1,4mm)
187.7% 187.1% 138.2% 116.0% 136.4% 119.7% 155.4% 159.0% 126.0% 139.9%
Table B.2: Differences in the maximum values between different smoothing values, nanoparticles solutions and three sized tubes. Original
PET data was used as reference, and deviations were calculated from this reference: Difference =
[(
recovered value
original value
)
− 1
]
× 100%.
Solution A Solution B
Dataset Small Small Medium Big Medium Big
tube 1 tube 2 tube 6 tube 5 tube 8 tube 7
PET 5652.6±425.9 5213.0±463.0 7691.5±637.2 12982.4±772.9 3682.2±110.2 6043.8±319.0
Corrected PET 1
(FWHM=0,8mm)
8667.6±1553.9 7871.5±1816.6 10415.5±2465.9 16186.7±3831.3 5051.2±982.8 7622.9±1968.9
Corrected PET 2
(FWHM=1,0mm)
9792.3±1965.8 8836.9±2269.7 11401.3±3087.0 17156.3±4988.8 5526.1±1278.7 8117.0±2561.6
Corrected PET 3
(FWHM=1,2mm)
10834.9±2320.1 9724.7±2657.4 12317.8±3602.0 18020.7±5995.7 5958.2±1527.4 8560.5±3081.2
Corrected PET 4
(FWHM=1,4mm)
12069.6±2731.0 10770.2±3102.0 13405.3±4178.7 19015.7±7167.4 6463.0±1808.8 9073.6±3684.9
Solution C
Dataset Small Small Medium Big
tube 3 tube 4 tube 9 tube 10
PET 788.5±54.4 500.3±302.4 832.4±253.6 3510.3±275.3
Corrected PET 1
(FWHM=0,8mm)
1189.8±218.9 726.1±494.5 1161.5±511.8 4709.4±1130.1
Corrected PET 2
(FWHM=1,0mm)
1331.2±271.8 801.2±570.0 1280.6±601.5 5144.3±1446.1
Corrected PET 3
(FWHM=1,2mm)
1459.3±313.6 867.4±640.3 1390.5±678.5 5548.1±1722.1
Corrected PET 4
(FWHM=1,4mm)
1608.3±358.7 943.0±724.0 1520.1±764.9 6026.8±2042.0
Table B.3: Mean values in kBq/ml of the tubes present in PET and Corrected PET data.
Solution A Solution B Solution C
Dataset Small Small Medium Big Medium Big Small Small Medium Big
tube 1 tube 2 tube 6 tube 5 tube 8 tube 7 tube 3 tube 4 tube 9 tube 10
PET — — — — — — — — — —
Corrected PET 1
(FWHM=0,8mm)
53.3% 51.0% 35.4% 24.7% 37.2% 26.1% 50.9% 45.2% 39.5% 34.2%
Corrected PET 2
(FWHM=1,0mm)
73.2% 69.5% 48.2% 32.2% 50.1% 34.3% 68.8% 60.2% 53.8% 46.6%
Corrected PET 3
(FWHM=1,2mm)
91.7% 86.5% 60.1% 38.8% 61.8% 41.6% 85.1% 73.4% 67.0% 58.1%
Corrected PET 4
(FWHM=1,4mm)
113.5% 106.6% 74.3% 46.5% 75.5% 50.1% 104.0% 88.5% 82.6% 71.7%
Table B.4: Differences in the mean values between different smoothing values, nanoparticles solutions and three sized tubes. Original
PET data was used as reference, and deviations were calculated from this reference: Difference =
[(
recovered value
original value
)
− 1
]
× 100%.
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